Tag Archives: investing ideas

MLP Returns In Your IRA Or Tax Protected Account: Number 3 In The Series

Two MLP CEFs that offer yields over 7% at current prices. Using these CEFs allows one to keep them in an IRA or Tax protected account without concern over the $1000.00 UBTI limit. Both of these CEFs is currently selling below NAV. This is the third article to cover various CEFs, ETFs and ETNs that cover high return issues like MLPs and REITs that are useful for an IRA and/or other tax deferred accounts. The first article in the series is here and the second is here . This piece examines several funds that were suggested in the comments section of my first article, NML and CEM . Neuberger Berman MLP Income Fund distributes payments monthly and currently pays $0.105 per share on the last day of the month. At a price of around $16.00 per share, the fund offers nearly an 8% yield. The chart below indicates that the fund is selling at its low for the year. (click to enlarge) Source: Interactive Brokers NML originated on 3/25/2013 as a CEF and the value of the fund has increased just short of 6% over the past 2 years. The fund is selling at about an 8% discount to NAV since the NAV was $18.43 as of 6/18/2015 and sold for about $17.00 per share on the same date. The CEF’s holdings as of 5/31/2015 are displayed below: (click to enlarge) Source: Neuberger Berman Web Site The current list of holdings is showing either a yield that is the same or greater than last year, which should indicate that the current dividend is relatively safe. However, there is no guarantee that there will not be decreases in the monthly payment at some future time if the prices of oil and gas don’t hold up. The managers of the fund are Douglas Rachlin with 29 years of investment experience and Yves Siegel who has 30 years of investment experience. Both managers personally own several thousand shares of the fund, assuring investors they have a vested in interest in the CEF doing well. The portfolio turnover ran at 10% for 2014 and expenses for the fund excluding income tax were 1.77%. Total expenses including income tax ran near 8%. Since the fund pays income tax on MLP earnings, one does not have to deal with a K-1 or have any concern about having this fund in an IRA. The fund uses leverage and recently updated its lending facility. The fund has the ability to finance $500 million of leverage with a $300 million floating rate facility and a $200 million fixed-rate facility. Clearbridge Energy MLP Fund Inc. (NYSE: CEM ) is a MLP closed end fund run by Legg Mason Global Asset Management. Total assets of the fund amount to $3.12 billion with quarterly distributions that have been increasing gradually since the fund was first started in 2010. Distributions started at $0.35 per share in 2010 with the latest distribution at $0.42 per share. This fund like the others covered in the series sends a 1099 at the end of year so an investor does not need to be concerned about K-1s. Michael Clarfeld, a CFA with 15 years of investment experience, Chris Eades with 23 years of investment experience and Peter Vanderlee, a CFA with 16 years of investment experience are the directors of the fund . The investment objective of the fund is to provide a high level of total return with an emphasis on cash distributions. The fund has grown both the dividend and the NAV since inception, see below: (click to enlarge) Source: Clearbridge Web Site The top 10 holdings of the fund are listed below: Source: Clearbridge Web Site One can see from the fund’s asset allocation below that it is not dependent upon drilling for oil and gas the dividend: Source: Clearbridge Web Site CEM recently completed a private placement of preferred stock and notes totaling $258 million to make new investments. So it is certain that the managers of the fund are planning to exercise leverage in the portfolio. The current expense ratio for this CEF is 2.19%. The current price of CEM is around $23.00 per share with a quarterly distribution of $0.42 per share so that the current yield of the fund is around 7.3%. The fund is selling about 7.5% below NAV just as NML is, so one can buy either of these funds at a discount to the actual worth of their holdings. The holdings of these 2 funds are somewhat different, so an investor desiring greater diversification with one’s MLP holdings could consider buying some of both funds. Conclusion: Both of these CEFs offers a yield over 7% at current market prices and is selling considerably below NAV. Although both have relatively high expense ratios, the leverage these CEFs uses helps cover these costs so that yields remain high. CEM has been in existence longer and has shown greater appreciation and growth in yield than NML and could be the better CEF. However, buying a bit of both gives one greater diversification in the MLP industry without having to deal with K-1s. Using these CEFs as well as others I have covered in the past allow one to have MLPs in a tax-protected account without the concern over the $1000.00 limit imposed by the IRS on UBTI. In addition, they also offer greater diversification and no concern about K-1s if one desires to use them in a regular account. Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

When Higher Volatility Leads To Lower Risk

Summary A method is presented for evaluating risk of investment portfolios in retirement. This analysis defines risk as the chance of going broke during retirement, rather than a portfolio’s volatility. For adaptive asset allocation portfolios studied here, increasing volatility leads to decreasing risk. Introduction Investors benefit from availability of low-cost exchange-traded and mutual funds, and from myriad choices of strategies and tactics for allocating assets to a portfolio of these funds. Investors also have access to web-based tools to back test portfolio return and volatility. Then they can use those results as inputs to other web-based tools, to estimate worst-case and median future performance, taking into account planned contributions to the portfolio (for workers) or withdrawals (for retirees). What seems missing, however, is a systematic method to combine these tools to gauge the suitability of a portfolio for an investor’s own circumstances, and to reach a buying decision. For example, consider a recently-retired investor who needs to withdraw 3% of his or her savings per year, evaluating a choice between two portfolios: one with back test results showing 10% volatility and 9% annual return, and the other showing 18% volatility and 15% annual return. This analysis illustrates a method for making such a choice. The method has limitations, because back tests can turn out to be poor predictors of out-of-sample (future) performance, and because investors can feel uncomfortable using past performance as the only input to a decision — excluding other sources such as expert opinions on macroeconomic or political situations. However, the proposed method has the merit of providing an unemotional way to make an asset-allocation decision, based on easily-available data and tools. Consider a retired person who: Invests an initial amount at the start of retirement, Withdraws a percentage of the initial amount each year, adjusted for inflation, and Follows an asset class allocation strategy for the duration of retirement. Some advisors define a portfolio’s risk as its volatility, where volatility is an estimate of the standard deviation of annual returns. This is not helpful for choosing between portfolios when one has higher volatility and higher return than the other. A retiree could define risk less abstractly, as the chance of running out of money during retirement. A prudent retiree would first seek to reduce that risk to a negligible level, to avoid the catastrophe of going broke. That ensured, the retiree would next seek to increase the balance at the end of retirement, to leave a legacy. Simulation method This analysis used a Monte Carlo simulation tool at portfoliovisualizer.com , with input parameters set as shown in the table below. For each combination of annual withdrawal and volatility shown in the table, the analysis tried various values of expected return, until the simulation output showed a 99% probability of success. This means that at the preset annual withdrawal and volatility settings, 99% of Monte Carlo trials showed a positive balance at the end of retirement. In other words, the retiree did not go broke. The expected return setting that yields 99% probability of success represents the average annual rate of return necessary throughout retirement, to reduce risk to a negligible level at the given settings for annual withdrawal and volatility. Defining negligible risk as 99% probability of success (1% risk) seems appropriate considering the severity of the consequences of running out of money. The simulation tool also provides a median end balance, which gives the retiree’s legacy at the end of retirement in 50% of Monte Carlo trials at the given withdrawal rate and volatility settings, and at the expected return necessary for 99% probability of success at those settings. The simulator shows median end balance discounted for inflation, and therefore expressed in the same dollars as the initial invested amount at the start of retirement. Initial amount $1,000,000 (in today’s dollars) Annual adjustment Withdraw fixed amount annually Annual withdrawal $30,000, $40,000, or $50,000 for 3%, 4% or 5% annual withdrawal rate Inflation adjusted Yes Simulation period (years) 30 Simulation model Parameterized Returns Distribution Fat-Tailed Distribution (Student’s t-distribution with 30 degrees of freedom) Expected return Varied for combination of annual withdrawal setting above and volatility setting below, to obtain 99% “Probability of success” (1% risk of zero balance at end of retirement) Volatility Repeated at 10%, 12%, 14%, 16%, 18%, or 20% Inflation model Historical inflation (4.18% mean and 3.14% standard deviation, based on CPI-U from 1972 to 2014) This procedure yielded (volatility, return) pairs at 1% risk of going broke, for withdrawing an inflation-adjusted fixed amount annually, equal to 3%, 4%, or 5% of the initial amount. It also provided the median end balance at this volatility, return, and withdrawal rate. Simulation results The simulation tool provided the results in the table below, where “Median annual return” = (Median end balance / Initial amount)^(1/30)-1, This equation gives the median annual rate of return during retirement after inflation and withdrawals, at the selected withdrawal rate (3%, 4%, or 5%), the selected volatility, and the rate of return required to reduce risk to 1%. Annual return for 99% success probability Median annual return after withdrawals Volatility 3% rate 4% rate 5% rate 3% rate 4% rate 5% rate 10% 9% 12% 13% 6% 8% 10% 12% 10% 13% 15% 7% 10% 11% 14% 12% 15% 16% 9% 12% 13% 16% 13% 16% 17% 11% 13% 14% 18% 15% 17% 19% 12% 14% 15% 20% 16% 19% 20% 13% 16% 17% Chart 1 below shows that annual return required for 99% success probability increases linearly with volatility over the volatility domain studied. A portfolio with volatility and annual return on or above the investor’s withdrawal percentage line has acceptable risk. If choosing between two back tested portfolios, one with 10% volatility and 9% annual return, and the other with 18% volatility and 15% annual return, an investor with a 3% annual withdrawal plan could choose either portfolio and meet the primary objective: negligible chance of going broke. Chart 1 begs a question, about the balance at the end of retirement, the investor’s legacy. Chart 2 below shows that median annual return also increases linearly with volatility over the volatility domain studied, at the annual return selected to reduce worst-case risk to 1% at a given volatility and withdrawal rate. It shows that for two portfolios with equal risk, an investor leaves a larger legacy by selecting the portfolio with higher volatility and higher return. Chart 2 also shows that the median annual return after withdrawals increases for higher withdrawal rate at the same volatility, which at first could appear counter-intuitive. This occurs because the higher withdrawal rate requires a higher annual return to reduce the worst-case risk to 1% at the same volatility, and this higher annual return outweighs the higher withdrawals. Application to portfolios Chart 1 begs another question: What annual returns and volatilities do back tests show for various asset-allocation strategies, and how do these compare with the “lines of 1% risk” in Chart 1? Consider a strategic portfolio (with fixed asset allocations) and several tactical portfolios (with adaptive asset allocations): Portfolio Rebalancing Composition Strategic Annual 40% 10-year T-note, 30% US large cap, 20% developed international, 10% emerging markets Tactical 1 Monthly Picks 1 of 6 ETFs for 3-month relative strength: EEM, IWM, MDY, QQQ, SPY, TLT Tactical 1a Monthly Same as Tactical 1, except moves assets to cash when price is below 3-month moving average Tactical 2 Monthly Same as Tactical 1, except picks 2 of 6 ETFs Tactical 2a Monthly Same as Tactical 2, except moves assets to cash when price is below 3-month moving average Tactical 3 Monthly Same as Tactical 1, except picks 3 of 6 ETFs Tactical 3a Monthly Same as Tactical 3, except moves assets to cash when price is below 3-month moving average The strategic portfolio results come from the “Backtest Portfolio” tool at portfoliovisualizer.com. The tactical portfolio results come from the “Timing Models” tool at the same website. The tactical portfolios are variants of one published in an article by Dr. Toma Hentea . The table below provides back test results for the portfolios defined above. Backtests 1972-2014 Portfolio CAGR StdDev Max drawdown Sharpe ratio Sortino ratio CAGR / StdDev Strategic 10.2% 11.6% -20.8% 0.49 0.95 0.88 Backtests 2007-2014 Portfolio CAGR StdDev Max drawdown Sharpe ratio Sortino ratio CAGR / StdDev Strategic 6.4% 10.3% -16.6% 0.57 0.92 0.62 Tactical 1 26.5% 17.7% -15.6% 1.35 2.77 1.50 Tactical 1a 19.7% 16.9% -13.7% 1.09 2.14 1.17 Tactical 2 18.7% 15.0% -27.8% 1.17 1.97 1.25 Tactical 2a 15.7% 13.1% -12.9% 1.10 2.05 1.19 Tactical 3 15.6% 15.0% -36.2% 0.98 1.62 1.04 Tactical 3a 14.5% 12.6% -14.4% 1.07 1.90 1.15 In addition to volatility (StdDev) and annual return (OTCPK: CAGR ), back test tools also provide a Sharpe ratio, Sortino ratio, and Max drawdown. Chart 3 below shows that the Sharpe and Sortino ratios do not contain much new information not already contained in the ratio CAGR/StdDev. Consequently this analysis focuses on CAGR and StdDev. Chart 4 below shows the “lines of 1% risk” from Chart 1, together with the back test results for the portfolios defined above. Chart 4 also shows a straight line fit to portfolio back tests from 2007-2014. The slope of this line exceeds the slopes of the lines of 1% risk, which implies that a retired investor could decrease risk by selecting a portfolio with higher volatility, when choosing from the set of portfolios studied here, because the benefit of higher return outweighs the disadvantage of higher volatility. Moreover, median legacy increases with volatility as shown in Chart 2. Back tests also provide “max drawdown”, which this analysis has not yet discussed. Chart 5 below shows that max drawdown seems to contain additional information not explained by CAGR/StdDev. Although max drawdown does not seem to affect retiree’s risk according to the analysis above, an investor could find it easier to “stay the course” with a less negative max drawdown: thus the interest of Portfolios 2a and 3a compared to 2 and 3. Alternative simulation results The preceding analysis assumed that a prudent investor would seek a 99% probability of success. The table below provides simulation results for 95% success probability, again at 3%, 4%, and 5% annual withdrawal rates. Annual return for 95% success probability Median annual return after withdrawals Volatility 3% rate 4% rate 5% rate 3% rate 4% rate 5% rate 10% 8% 10% 11% 4% 6% 7% 12% 9% 11% 13% 5% 6% 8% 14% 10% 12% 14% 6% 8% 9% 16% 11% 13% 15% 8% 9% 10% 18% 12% 14% 16% 8% 10% 12% 20% 13% 15% 17% 9% 11% 13% Chart 6 shows required annual return versus volatility for 95% probability of success. Comparison with Chart 1 demonstrates that this less-stringent requirement for probability of success results in less-stringent requirements for annual returns, at the same volatilities. Chart 7 shows median annual return after inflation and withdrawals, versus volatility, for 95% probability of success. Comparison with Chart 2 demonstrates that this less-stringent requirement annual returns results in lower legacies, at the same volatility. Discussion and conclusion Investors could use this method to select among asset allocation portfolios of widely-available ETFs or mutual funds. For the portfolios studied here, it seems that an adaptive asset allocation portfolio with higher volatility would be a good place to start. The method will confirm when higher returns outweigh higher volatility, to result in a lower risk and a larger legacy. Investors should check the maximum drawdown of the selected portfolio, to ensure that they can stick with the program. Note that even a 1% risk of going broke during retirement can feel unacceptable, considering the severity of the consequences and the small chance of finding work again. Adaptive asset allocation could provide an alternative to traditional equity portfolios, but it still feels important to maintain a permanent allocation to real estate, cash, and short-term US Treasury bills — in case the 1% event occurs. Disclosure: I am/we are long SPY. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

40% Return In ~4 Months With Our IP Selected Healthcare Companies Since SA Publication

Summary Portfolio consisting of 17 healthcare companies would have returned nearly 40% from February 10th 2015 (date of article publication on SA) to June 18th 2015. Outperformance exclusively obtained with Patent Dynamics/Patterns (IP models) with XBI, FBT and IBB as benchmarks. Expert and/or financial analysis may be combined with such IP models for even better returns. Tickers covered: JAZZ, SAGE, TNXP, SGYP, ASPX, XNPT, INSM, RNN, NVDQ, ZSPH, ACUR, ICPT, RDHL, CORI, SPNC, EBIO and HAE. We wanted to know how the ” 17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes ” performed since SA publication on February 10th 2015, namely JAZZ, SAGE, TNXP, SGYP, ASPX, XNPT, INSM, RNN, NVDQ, ZSPH, ACUR, ICPT, RDHL, CORI, SPNC, EBIO and HAE. Results below are impressive taking into account that these companies were only selected using Patent Dynamics/Patterns within these companies. This represents another evidence of the utility to take into account Patent Dynamics/Patterns in any investment selection process. Moreover, complementing or combining such patent filtering criteria with a financial/expert analysis and/or active management would have probably resulted in an even higher return on investment. Results: I. Performance of the 17 companies from February 10 th 2015 to June 18 th 2015 COMPANY TICKER EXCHANGE PERF% Synergy Pharmaceuticals SGYP NDQ 211.90 Corium International CORI NDQ 109.67 Sage Therapeutics SAGE NDQ 97.65 Acura Pharmaceuticals ACUR NDQ 83.33 Tonix Pharmaceuticals TNXP NDQ 77.55 Auspex Pharmaceuticals Inc ASPX NDQ 65.48 Redhill Biopharma Ltd RDHL NDQ 55.19 Insmed, Inc. INSM NDQ 51.36 Intercept Pharmaceuticals ICPT NDQ 32.01 ZS Pharma, Inc. ZSPH NDQ 24.15 Jazz Pharmaceuticals JAZZ NDQ 7.55 Haemonetics Corp HAE NYS 0.21 XenoPort, Inc. XNPT NDQ -3.34 Rexahn Pharmaceuticals, Inc. RNN NYS -9.33 Novadaq Technologies NVDQ NDQ -15.91 The Spectranetics Company SPNC NDQ -19.17 Eleven Biotherapeutics EBIO NDQ -74.21 70% of the companies have positive performance (30% negative). To note that ASPX was acquired by Teva Pharmaceuticals ( announcement on March 2015 ). II. What would have been the return of a portfolio composed of these 17 companies? A portfolio consisting of these 17 healthcare companies would have returned nearly 40% from February 10 th 2015 to June 18 th 2015 (in a bit more than four months) . This is to be compared with biotech ETFs like XBI, FBT or IBB returning respectively 26.66%, 15.67% and 18.73%. Hence, this represents a strong outperformance by applying Patent Dynamics/Patterns only versus benchmarks. Return is based on an equally weighted portfolio rebalanced each month. Cumulative performance of the 17 healthcare companies versus benchmarks (XBI, FBT and IBB) (click to enlarge) Table: Monthly performance and cumulative return of the 17 healthcare companies versus benchmarks (XBI, FBT and IBB) DATE MONTHLY PERF 17 Healthcare XBI-MONTH XBI FBT-MONTH FBT IBB-MONTH IBB 10.02.2015 N/A 100.00 N/A 100.00 N/A 100.00 N/A 100.00 10.03.2015 11.05 111.05 13.60 113.60 9.97 109.97 7.28 107.28 10.04.2015 7.75 119.66 1.77 115.61 2.02 112.19 4.69 112.31 11.05.2015 -1.32 118.08 -1.70 113.65 -2.18 109.75 -1.44 110.69 10.06.2015 8.26 127.84 7.38 122.03 3.17 113.22 3.84 114.95 18.06.2015 9.40 139.86 3.79 126.66 2.16 115.67 3.29 118.73 Focusing only on the Rating provided by the IP model (see article), we might have done even better in terms of performance by changing the weight of each company as the worst performer EBIO (-74.2%) had a Rating of D (worst form Ratings from A to D), whereas the two best performers SGYP (+211.9%) and CORI (+109.67%) had A Ratings. As mentioned, financial analysis and/or active management might have contributed as well to improve the performance. If we take for example the worst performer EBIO, disappointing results were released . Taking into account financial and/or expert analysis, one would have probably sold or reduced the weight of EBIO, see for example financial analysis indicated that caution was warranted , precursor sell signal or the comment from SA user businessofbiotech : “Eleven Bio’s lead product candidate fails in Phase 3 study; shares plunge 78% [ View news story ] Anyone with the slightest knowledge of dry eye and bit more attention to the press release of Phase 2 results would have never invested in this company. In their press release they mentioned they achieved statistical significance from baseline to end of tx, but not between the groups. They gave the false impression that their drug worked by showing decrease in the frequency of artificial tears (not an FDA approvable endpoint). The CEO knew the drug was a bust and she still took the company public on the false hope of their technology platform. Now she is trying to sell the hope that this drug will work in allergic conjunctivitis….One word- RUNNNN!!!” What to do next? The IP models provide some indications on what to do with those companies at the present time as their Grade, Score or Patent Index might have changed since the February publication (some slight modifications have been made to the models so the grade as published in February 2015 might not always correspond to the ones in the table below). The following recommendations are therefore only based on the IP models (with the exception of recent run up). It is recommended to combine the present IP approach with a financial and/or expert analysis. For JAZZ, Grade has changed from A to C, with a Score declining from 2 to 1, and with a present Patent Index (PI=3) smaller than the maximum Patent Index (PIMax=4). A PI